Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity

Journal of Immunology

Volumn 186, Issue 2, 2011, Pages 1218-1227

  Tsuji, Takemasa ^a   Matsuzaki, Junko ^b   Kelly, Marcus P ^a   Ramakrishna, Venky ^c   Vitale, Laura ^c   He, Li Zhen ^c   Keler, Tibor ^c   Odunsi, Kunle ^b   Old, Lloyd J ^a   Ritter, Gerd ^a   Gnjatic, Sacha ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Celldex Therapeutics Inc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; DEC 205 RECEPTOR; MANNOSE RECEPTOR; MONOCLONAL ANTIBODY; NY ESO 1 ANTIGEN; NY ESO 1 MONOCLONAL ANTIBODY; RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEIN TRANSPORT; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CLONE CELLS; CROSS-PRIMING; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; LECTINS, C-TYPE; MANNOSE-BINDING LECTINS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS;

EID: 79251591959     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000808     Document Type: Article

References (43)

1. Chen, Y. T., M. J. Scanlan, U. Sahin, O. Türeci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918.
2. Gnjatic, S., H. Nishikawa, A. A. Jungbluth, A. O. Güre, G. Ritter, E. Jäger, A. Knuth, Y. T. Chen, and L. J. Old. 2006. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 95: 1-30.
3. Stockert, E., E. Jäger, Y. T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L. J. Old. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187: 1349-1354.
4. Jäger, E., Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jäger, M. Arand, H. Wada, Y. Noguchi, E. Stockert, et al. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187: 265-270.
5. Jäger, E., Y. Nagata, S. Gnjatic, H. Wada, E. Stockert, J. Karbach, P. R. Dunbar, S. Y. Lee, A. Jungbluth, D. Jäger, et al. 2000. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA 97: 4760-4765.
6. Gnjatic, S., D. Atanackovic, E. Jäger, M. Matsuo, A. Selvakumar, N. K. Altorki, R. G. Maki, B. Dupont, G. Ritter, Y. T. Chen, et al. 2003. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl. Acad. Sci. USA 100: 8862-8867.
7. Valmori, D., N. E. Souleimanian, V. Tosello, N. Bhardwaj, S. Adams, D. O'Neill, A. Pavlick, J. B. Escalon, C. M. Cruz, A. Angiulli, et al. 2007. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl. Acad. Sci. USA 104: 8947-8952.
8. Odunsi, K., F. Qian, J. Matsuzaki, P. Mhawech-Fauceglia, C. Andrews, E. W. Hoffman, L. Pan, G. Ritter, J. Villella, B. Thomas, et al. 2007. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. USA 104: 12837-12842.
9. Davis, I. D., W. Chen, H. Jackson, P. Parente, M. Shackleton, W. Hopkins, Q. Chen, N. Dimopoulos, T. Luke, R. Murphy, et al. 2004. Recombinant NYESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. USA 101: 10697-10702.
10. Jager, E., J. Karbach, S. Gnjatic, A. Neumann, A. Bender, D. Valmori, M. Ayyoub, E. Ritter, G. Ritter, D. Jager, et al. 2006. Recombinant vaccinia/ fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA 103: 14453-14458.
11. Uenaka, A., H. Wada, M. Isobe, T. Saika, K. Tsuji, E. Sato, S. Sato, Y. Noguchi, R. Kawabata, T. Yasuda, et al. 2007. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 7: 9.
12. Adams, S., D. W. O'Neill, D. Nonaka, E. Hardin, L. Chiriboga, K. Siu, C. M. Cruz, A. Angiulli, F. Angiulli, E. Ritter, et al. 2008. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181: 776-784.
13. Nishikawa, H., F. Qian, T. Tsuji, G. Ritter, L. J. Old, S. Gnjatic, and K. Odunsi. 2006. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J. Immunol. 176: 6340-6346.
14. Le Gal, F. A., M. Ayyoub, V. Dutoit, V. Widmer, E. Jäger, J. C. Cerottini, P. Y. Dietrich, and D. Valmori. 2005. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J. Immunother. 28: 252-257.
15. Sharma, P., D. F. Bajorin, A. A. Jungbluth, H. Herr, L. J. Old, and S. Gnjatic. 2008. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J. Immunother. 31: 849-857.
16. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
17. Tacken, P. J., I. J. de Vries, R. Torensma, and C. G. Figdor. 2007. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7: 790-802.
18. Bozzacco, L., C. Trumpfheller, F. P. Siegal, S. Mehandru, M. Markowitz, M. Carrington, M. C. Nussenzweig, A. G. Piperno, and R. M. Steinman. 2007. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc. Natl. Acad. Sci. USA 104: 1289-1294.
19. Hawiger, D., K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M. Rivera, J. V. Ravetch, R. M. Steinman, and M. C. Nussenzweig. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769-779.
20. He, L. Z., A. Crocker, J. Lee, J. Mendoza-Ramirez, X. T. Wang, L. A. Vitale, T. O'Neill, C. Petromilli, H. F. Zhang, J. Lopez, et al. 2007. Antigenic targeting of the human mannose receptor induces tumor immunity. J. Immunol. 178: 6259-6267.
21. He, L. Z., V. Ramakrishna, J. E. Connolly, X. T. Wang, P. A. Smith, C. L. Jones, M. Valkova-Valchanova, A. Arunakumari, J. F. Treml, J. Goldstein, et al. 2004. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin. Cancer Res. 10: 1920-1927.
22. Ramakrishna, V., J. F. Treml, L. Vitale, J. E. Connolly, T. O'Neill, P. A. Smith, C. L. Jones, L. Z. He, J. Goldstein, P. K. Wallace, et al. 2004. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs antimelanoma T cell responses via multiple HLA molecules. J. Immunol. 172: 2845-2852.
23. Ramakrishna, V., J. P. Vasilakos, J. D. Tario, Jr., M. A. Berger, P. K. Wallace, and T. Keler. 2007. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J. Transl. Med. 5: 5.
24. Bonifaz, L. C., D. P. Bonnyay, A. Charalambous, D. I. Darguste, S. Fujii, H. Soares, M. K. Brimnes, B. Moltedo, T. M. Moran, and R. M. Steinman. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199: 815-824.
25. Butler, M., A. S. Morel, W. J. Jordan, E. Eren, S. Hue, R. E. Shrimpton, and M. A. Ritter. 2007. Altered expression and endocytic function of CD205 in human dendritic cells, and detection of a CD205-DCL-1 fusion protein upon dendritic cell maturation. Immunology 120: 362-371.
26. Kato, M., K. J. McDonald, S. Khan, I. L. Ross, S. Vuckovic, K. Chen, D. Munster, K. P. MacDonald, and D. N. Hart. 2006. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int. Immunol. 18: 857-869.
27. Nagata, Y., S. Ono, M. Matsuo, S. Gnjatic, D. Valmori, G. Ritter, W. Garrett, L. J. Old, and I. Mellman. 2002. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc. Natl. Acad. Sci. USA 99: 10629-10634.
28. Matsuo, M., Y. Nagata, E. Sato, D. Atanackovic, D. Valmori, Y. T. Chen, G. Ritter, I. Mellman, L. J. Old, and S. Gnjatic. 2004. IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc. Natl. Acad. Sci. USA 101: 14467-14472.
29. Atanackovic, D., N. K. Altorki, Y. Cao, E. Ritter, C. A. Ferrara, G. Ritter, E. W. Hoffman, C. Bokemeyer, L. J. Old, and S. Gnjatic. 2008. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl. Acad. Sci. USA 105: 1650-1655.
30. Atanackovic, D., M. Matsuo, E. Ritter, G. Mazzara, G. Ritter, E. Jäger, A. Knuth, L. J. Old, and S. Gnjatic. 2003. Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J. Immunol. Methods 278: 57-66.
31. Sharma, P., S. Gnjatic, A. A. Jungbluth, B. Williamson, H. Herr, E. Stockert, G. Dalbagni, S. M. Donat, V. E. Reuter, D. Santiago, et al. 2003. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun. 3: 19.
32. Gnjatic, S., Y. Nagata, E. Jager, E. Stockert, S. Shankara, B. L. Roberts, G. P. Mazzara, S. Y. Lee, P. R. Dunbar, B. Dupont, et al. 2000. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl. Acad. Sci. USA 97: 10917-10922.
33. Odunsi, K., A. A. Jungbluth, E. Stockert, F. Qian, S. Gnjatic, J. Tammela, M. Intengan, A. Beck, B. Keitz, D. Santiago, et al. 2003. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 63: 6076-6083.
34. Qian, F., S. Gnjatic, E. Jäger, D. Santiago, A. Jungbluth, C. Grande, S. Schneider, B. Keitz, D. Driscoll, G. Ritter, et al. 2004. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun. 4: 12.
35. Matsuzaki, J., F. Qian, I. Luescher, S. Lele, G. Ritter, P. A. Shrikant, S. Gnjatic, L. J. Old, and K. Odunsi. 2008. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol. Immunother. 57: 1185-1195.
36. Kane, N., R. Kelly, P. T. Saunders, and H. O. Critchley. 2009. Proliferation of uterine natural killer cells is induced by human chorionic gonadotropin and mediated via the mannose receptor. Endocrinology 150: 2882-2888.
37. Lonberg, N., L. D. Taylor, F. A. Harding, M. Trounstine, K. M. Higgins, S. R. Schramm, C. C. Kuo, R. Mashayekh, K. Wymore, J. G. McCabe, et al. 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368: 856-859.
38. Zeng, G., M. E. Aldridge, X. Tian, D. Seiler, X. Zhang, Y. Jin, J. Rao, W. Li, D. Chen, M. P. Langford, et al. 2006. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J. Immunol. 177: 3582-3589.
39. Pavelic, V., M. S. Matter, S. Mumprecht, I. Breyer, and A. F. Ochsenbein. 2009. CTL induction by cross-priming is restricted to immunodominant epitopes. Eur. J. Immunol. 39: 704-716.
40. Wolkers, M. C., N. Brouwenstijn, A. H. Bakker, M. Toebes, and T. N. Schumacher. 2004. Antigen bias in T cell cross-priming. Science 304: 1314-1317.
41. Boscardin, S. B., J. C. Hafalla, R. F. Masilamani, A. O. Kamphorst, H. A. Zebroski, U. Rai, A. Morrot, F. Zavala, R. M. Steinman, R. S. Nussenzweig, and M. C. Nussenzweig. 2006. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203: 599-606.
42. Pasare, C., and R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
43. Nishikawa, H., T. Tsuji, E. Jäger, G. Briones, G. Ritter, L. J. Old, J. E. Galán, H. Shiku, and S. Gnjatic. 2008. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 111: 1404-1412.